Filing Flows › AbCellera Biologics (ABCL) › Q3 2026 › vs Q2 2026
AbCellera Biologics (ABCL) Q3 2026 vs Q2 2026 (quarter over quarter)
AbCellera Biologics's revenue rose $6.6M (+163%) from $4.0M in Q2 2026 to $10.6M in Q3 2026. The biggest changes: Research fees +$6.6M (+170%); Licensing and royalty revenue −$59K (-40%).
AbCellera Biologics, Q3 2026: revenue $10.6M (+19% year over year), operating margin -501.1%, net loss $40.8M, operating cash flow $26.9M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 237.8% | 587.4% | -349.6 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Research fees | $10.5M | $3.9M | $6.6M | +170% |
| Licensing and royalty revenue | $90K | $149K | −$59K | -40% |
| Revenue | $10.6M | $4.0M | $6.6M | +163% |
| Other income, net | $10.5M | $3.8M | $6.7M | +176% |
| Income tax benefit | $2.1M | $3.5M | −$1.5M | -42% |
| Net loss | $40.8M | $55.4M | −$14.7M | -26% |
| Costs & expenses | $64.0M | $66.8M | −$2.9M | -4% |
| Operating costs | $64.0M | $66.8M | −$2.9M | -4% |
| Research & development | $43.5M | $46.0M | −$2.5M | -5% |
| SG&A | $13.6M | $13.8M | −$237K | -2% |
| Other operating costs | $6.8M | $7.0M | −$184K | -3% |
| Operating cash sources | $67.7M | $81.3M | −$13.7M | -17% |
| Depreciation & amortization | $6.8M | $7.0M | −$184K | -3% |
| Share-based compensation | $11.7M | $12.3M | −$618K | -5% |
| Working capital & other | $49.2M | $62.1M | −$12.9M | -21% |
| Net loss absorbed | $40.8M | $55.4M | −$14.7M | -26% |
| Operating cash flow | $26.9M | $25.9M | $990K | +4% |
| Free cash flow (OCF − capex) | $25.3M | $23.8M | $1.5M | +6% |
| Capital expenditures | $1.6M | $2.1M | −$518K | -24% |
Questions
How much did AbCellera Biologics's revenue grow quarter over quarter in Q3 2026?
AbCellera Biologics's revenue rose $6.6M (+163%) from $4.0M in Q2 2026 to $10.6M in Q3 2026.
What drove AbCellera Biologics's revenue change in Q3 2026?
Research fees +$6.6M (+170%); Licensing and royalty revenue −$59K (-40%).